Spots Global Cancer Trial Database for glioblastoma multiforme
Every month we try and update this database with for glioblastoma multiforme cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | NCT00672243 | Glioblastoma Gliosarcoma | Erlotinib + sir... | 18 Years - | Duke University | |
| Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | NCT04869449 | Glioblastoma Glioblastoma Mu... Glioblastoma Mu... Glioblastoma Mu... | Ketoconazole | 18 Years - | Milton S. Hershey Medical Center | |
| Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients | NCT01089868 | Glioblastoma Mu... | 18 Years - | Ludwig-Maximilians - University of Munich | ||
| Neoadjuvant Nivolumab in Glioblastoma | NCT02550249 | Glioblastoma Mu... | Nivolumab | 1 Year - | Clinica Universidad de Navarra, Universidad de Navarra | |
| Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | NCT05432375 | Glioblastoma Mu... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells | NCT03980249 | Glioblastoma Glioblastoma Mu... | Carvedilol | 18 Years - | West Virginia University | |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma | NCT05954858 | Glioma, Maligna... Glioblastoma Glioblastoma Mu... Glioblastoma Mu... High Grade Glio... GBM Brain Cancer | Tissue autograf... | 18 Years - | Northwell Health | |
| Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT02997423 | Glioblastoma | 21 Years - | University of Iowa | ||
| Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | NCT00302159 | High Grade Glio... Brain Tumors | adjuvant therap... Temozolomide Valproic Acid Radiation thera... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | |
| Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | NCT01269853 | Glioblastoma Mu... Anaplastic Astr... | Bevacizumab Bevacizumab | 18 Years - | Northwell Health | |
| Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM | NCT04471844 | Glioblastoma Mu... | Optune® | 18 Years - | NovoCure Ltd. | |
| Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study) | NCT02300532 | Malignant Gliom... | No intervention | - | Eisai Inc. | |
| Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | NCT00290771 | Recurrent Gliob... | Imatinib tablet... Hydroxyurea cap... | 18 Years - | Novartis | |
| Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) | NCT00916409 | Glioblastoma Mu... | NovoTTF-100A de... Temozolomide | 18 Years - | NovoCure Ltd. | |
| Tamoxifen Versus Etoposide After First Recurrence in GBM Patients | NCT04765098 | Glioblastoma Mu... | Tamoxifen Etoposide | 18 Years - 65 Years | AHS Cancer Control Alberta | |
| Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) | NCT00311857 | Glioblastoma Mu... | Cetuximab Temozolomide Radiation thera... | 18 Years - 70 Years | Heidelberg University | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma | NCT06016452 | Diffuse Glioma Radionecrosis o... High Grade Glio... Glioblastoma Mu... | Chlorophyllin | 18 Years - 70 Years | Tata Memorial Centre | |
| Determination of Immune Phenotype in Glioblastoma Patients | NCT02751138 | Glioblastoma Mu... | Surgery | 18 Years - | University of Ulm | |
| A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma | NCT01474239 | Glioblastoma Mu... | bevacizumab [Av... fotemustine | 18 Years - | Hoffmann-La Roche | |
| Targeted Pediatric High-Grade Glioma Therapy | NCT05839379 | High Grade Glio... Diffuse Intrins... Anaplastic Astr... Glioblastoma Glioblastoma Mu... Diffuse Midline... Metastatic Brai... WHO Grade III G... WHO Grade IV Gl... | 12 Months - 39 Years | Nationwide Children's Hospital | ||
| The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma | NCT02189109 | Glioblastoma Mu... | NVX-108 | 18 Years - 70 Years | NuvOx LLC | |
| ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy | NCT03712293 | Glioblastoma Mu... | BBB Disruption ... | 19 Years - 80 Years | InSightec | |
| Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma | NCT03707457 | Glioblastoma Glioblastoma Mu... | Nivolumab Anti-GITR Monoc... IDO1 inhibitor ... Ipilimumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma | NCT04900792 | Glioblastoma Glioblastoma Mu... | Ferumoxytol inj... Pharmacological... External beam r... Temozolomide | 18 Years - | University of Iowa | |
| Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | NCT00041587 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Engagement of Patients With Advanced Cancer | NCT02966509 | End of Life Advanced Cancer Lung Neoplasm Gastric Cancer Colon Cancer Glioblastoma Mu... Head and Neck N... Rectum Cancer Melanoma Kidney Cancer Prostate Cancer Testicular Neop... Liver Cancer Cancer of Unkno... | EPAC | 18 Years - | Stanford University | |
| Low Dose Naltrexone for Glioma Patients | NCT01303835 | Malignant Gliom... | LDN Placebo | 18 Years - | Duke University | |
| Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) | NCT00797940 | Glioblastoma Mu... | IL-4PE | 18 Years - | Protox Inc. | |
| PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 | NCT01540513 | Glioblastoma Mu... Brain Metastase... | NM404 NM404 | 18 Years - | University of Wisconsin, Madison | |
| Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma | NCT01898273 | Glioblastoma | I-124-CLR1404 | 18 Years - | Cellectar Biosciences, Inc. | |
| Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma | NCT02067156 | Glioblastoma Mu... | G-202 | 18 Years - | GenSpera, Inc. | |
| Bevacizumab With or Without Surgery for Adult Glioblastomas | NCT01413438 | Glioblastoma Brain Neoplasm | Craniotomy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | NCT02858895 | Glioblastoma Grade IV Astroc... Glioblastoma Mu... Grade IV Glioma | MDNA55 | 18 Years - | Medicenna Therapeutics, Inc. | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | NCT00730262 | Glioblastoma Mu... | TLN-4601 | 18 Years - | Thallion Pharmaceuticals | |
| Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme | NCT01450449 | Glioblastoma Mu... | Radiotherapy Radiotherapy | 50 Years - | International Atomic Energy Agency | |
| Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02663440 | Glioblastoma Mu... | Hypofractionate... Granulocyte-mac... Temozolomide | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | NCT01582152 | Brain Neoplasms Central Nervous... | TPI287 Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Dendritic Cell Cancer Vaccine for High-grade Glioma | NCT01213407 | Glioblastoma Mu... | Trivax, Temozol... Temozolomide, S... | 3 Years - 70 Years | Activartis Biotech | |
| CT Perfusion in the Prognostication of Cerebral High Grade Glioma | NCT01923922 | Glioblastoma Mu... | CT Perfusion | 15 Years - | Nova Scotia Health Authority | |
| Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | NCT01266031 | Malignant Gliom... Recurrent Gliob... | vorinostat bevacizumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma | NCT02026271 | Glioblastoma Mu... Anaplastic Olig... | Ad-RTS-hIL-12 veledimex | 18 Years - 75 Years | Alaunos Therapeutics | |
| Bevacizumab and Lomustine for Recurrent GBM | NCT01290939 | Glioblastoma Mu... Cognition Disor... Disability Eval... | bevacizumab lomustine DNA methylation... laboratory biom... cognitive asses... quality-of-life... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Regorafenib in Relapsed Glioblastoma | NCT02926222 | Glioblastoma Mu... | Regorafenib Lomustine | 18 Years - | Istituto Oncologico Veneto IRCCS | |
| Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | NCT00031083 | Glioblastoma Mu... Anaplastic Astr... Oligoastrocytom... Gliosarcoma | Interferon-beta | 18 Years - | Biogen | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) | NCT00735436 | Malignant Gliom... Glioblastoma Mu... Gliosarcoma | Gliadel/Avastin... | 18 Years - | Duke University | |
| Vacuolar ATPase and Drug Resistance of High Grade Gliomas | NCT05328089 | Glioblastoma Mu... | 18 Years - 90 Years | University of Milano Bicocca | ||
| Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | NCT01607905 | Solid Tumor | Selinexor Acetaminophen | 18 Years - | Karyopharm Therapeutics Inc | |
| AMG 102 and Avastin for Recurrent Malignant Glioma | NCT01113398 | Glioblastoma Mu... Gliosarcoma | AMG 102 Avastin | 18 Years - | Duke University | |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | NCT04421378 | Glioblastoma Mu... | Selinexor Temozolomide (T... Lomustine (CCNU... Standard Fracti... Bevacizumab TTField Carmustine | 18 Years - | Karyopharm Therapeutics Inc | |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma | NCT03119064 | Glioblastoma Mu... Glioblastoma GBM | Nanoliposomal I... Temozolomide | 18 Years - | Brown University | |
| Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme | NCT05589961 | Glioblastoma Mu... | TMZ | 18 Years - 75 Years | The Second Hospital of Hebei Medical University | |
| APG101 in Glioblastoma | NCT01071837 | Glioblastoma Mu... | APG101 Blood drawing | 18 Years - | Apogenix AG | |
| LAM561 With RT and TMZ for Adults With Glioblastoma | NCT04250922 | Primary Gliobla... Glioblastoma Mu... | LAM561 TMZ RT | 18 Years - 75 Years | Laminar Pharmaceuticals | |
| A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma | NCT01562197 | Glioblastoma Mu... | axitinib Axitinib plus L... | 18 Years - 99 Years | Universitair Ziekenhuis Brussel | |
| A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | NCT02296476 | Glioblastoma Mu... | Birabresib | 18 Years - | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | |
| 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme | NCT03291990 | Glioblastoma Mu... | Temozolomide | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab | NCT06011109 | Glioma Glioblastoma Mu... | APG-157 | 19 Years - | Aveta Biomics, Inc. | |
| Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | NCT00050986 | Glioblastoma Mu... | Temozolomide R115777 | - | M.D. Anderson Cancer Center | |
| Radiotherapy for Malignant Astrocytomas in the Elderly | NCT00430911 | Primary Brain T... Anaplastic Astr... Glioblastoma Mu... | Radiotherapy | 70 Years - | Assistance Publique - Hôpitaux de Paris | |
| Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer | NCT01048008 | Advanced Cancer Brain Involveme... | DM-CHOC-PEN | 18 Years - | DEKK-TEC, Inc. | |
| Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | NCT00501891 | Glioblastoma Mu... | Bevacizumab Metronomic Temo... | 18 Years - | Duke University | |
| Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | NCT00376103 | Glioblastoma Mu... | temozolomide Brachytherapy External Beam R... | 18 Years - | Methodist Healthcare | |
| Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens | NCT02864368 | Glioblastoma Glioblastoma Mu... | 5-day TMZ 21-day TMZ PEP-CMV: Compon... Tetanus-Diphthe... Tetanus Pre-Con... PEP-CMV: Compon... | 18 Years - | Duke University | |
| Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | NCT00612339 | Glioblastoma Gliosarcoma | Avastin and Tem... | 18 Years - | Duke University | |
| Chlorpromazine and Standard of Care in Glioblastoma | NCT05190315 | Glioblastoma Mu... | Chlorpromazine Temozolomide Radiation Thera... | 18 Years - | University of Iowa | |
| Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | NCT00635557 | Glioblastoma Mu... | MPC-6827 + Carb... | 18 Years - | Myrexis Inc. | |
| Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | NCT00984438 | Glioblastoma Mu... | BCNU Wafer Irinotecan Bevacizumab | 18 Years - | University of Cincinnati | |
| Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme | NCT01435395 | Glioblastoma Mu... | Temozolomide, b... | 18 Years - | Emory University | |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | NCT00539344 | Recurrent or Pr... | ANG1005 | 18 Years - | Angiochem Inc | |
| Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors | NCT02038218 | Primary Brain T... Metastatic Mali... | 4-Demethyl-4-ch... | 18 Years - | DEKK-TEC, Inc. | |
| MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) | NCT04874506 | Glioblastoma Glioblastoma Mu... | MBM-02 | 35 Years - 75 Years | Matrix Biomed, Inc. | |
| PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma | NCT01112527 | Glioblastoma GBM Glioblastoma Mu... | PF-00299804 | 18 Years - | Massachusetts General Hospital | |
| A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) | NCT00990496 | Glioblastoma Mu... | Fludarabine Cyclophosphamid... CMV Specific Cy... | 5 Years - 65 Years | Milton S. Hershey Medical Center | |
| Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. | NCT01301430 | Glioblastoma Mu... | H-1PV | 18 Years - | Oryx GmbH & Co. KG |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
